IN THE CLAIMS:

1-3. (Canceled)

- 4. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of an Mts1 protein.
- 5. (Original) The isolated multimeric Mts1 protein complex of claim 4, having a Mw in the range of about 30 kD to about 200 kD.
- 6. (Currently amended) The isolated multimeric Mts1 protein complex of claim 4, wherein <u>said</u> Mts1 protein is a wild type Mts1 protein.
- 7. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of Mts1-del75.
- 8. (Previously presented) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts1 protein is of a mammalian origin.

9. (Canceled)

- 10. (Original) A pharmaceutical composition comprising the isolated complex of claim 4, and a pharmaceutically acceptable carrier.
- 11. (Previously presented) The pharmaceutical composition of claim 10, wherein said pharmaceutically acceptable carrier is liquid, semi-solid, or solid.
- 12. (Previously presented) The pharmaceutical composition of claim 10, further comprising a neurotropic factor.

13. (Original) The pharmaceutical composition of claim 12, wherein said neurotropic factor is selected from the group consisting of bFGF, aFGF, CNTF, NGF, BDNF, GDNF, NT3, NT4/5, IGF-1 and IGF-II.

14-25. (Canceled)

- 26. (Previously presented) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts-1 protein is a human Mts-1 protein.
- 27. (Previously presented) The isolated multimeric Mts1 protein complex of claim 26, wherein said human Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 1.
- 28. (Previously presented) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 2.
- 29. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of human Mts1-del75.